Trial Profile
Single Arm Phase II Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Apr 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 08 Apr 2024 Planned End Date changed from 1 Apr 2024 to 1 Apr 2025.
- 08 Apr 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Apr 2025.
- 06 Apr 2023 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.